The program supports investigator-sponsored clinical studies (ISS) or investigator-initiated trials (IIT). Our goal: to offer researchers and clinicians the opportunity to explore new indications, expand the use of Pentalafen®/Heliance® combination therapy, and push the boundaries of photodynamic therapy in cancer treatment.
The ISS program is open to European and American surgeons and oncologists and allows clinical teams to integrate the Pentalafen®/Heliance® combination therapy and its technologies into their clinical research and innovation programs.
Targeted areas of research
Hemerion is focusing on research initiatives in the following areas:
- Clinical neuro-oncology (rare central nervous system disorders or metastatic diseases)
- Translational science: analysis of biomarkers for tumor selectivity and histopathological analysis of the effects of photodynamic therapy (PDT) on the tumor microenvironment (TME).
- Pipeline expansion (feasibility studies in non-CNS tumors)
Our goal is to promote the implementation of clinical studies that complement our own in order to advance photodynamic therapy (PDT) and improve cancer patients’ survival rates and quality of life.
We support clinical research initiatives based on Hemerion technology
Hemerion can support these initiatives in many ways:
- Provision of GMP-grade Pentalafen® (investigational product).
- Loan of the Heliance® controller and supply of sterile diffusers. Most importantly, we provide comprehensive technical training for neurosurgical and operating room teams to ensure the safe and effective use of the system.
- Subject to Fair Market Value (FMV) assessments, grants may be awarded to cover study-related costs, such as data management, ethics committee fees, and patient screening.
- Access to investigator brochures (IBs), preclinical data, and consultation with our teams is also available.
